A scaling multinational strengthens its story for growth
01. The Context
A manufacturing platform with an unmatched biological trademark library was expanding from its origin market into more sophisticated international geographies. Early commercial traction in these new markets was below expectations, driven in part by a public-facing story that remained rooted in the home geography. This limited the company’s ability to compete, command trust and communicate value to global buyers, distributors, partners and future investors.
02. The Strategic Need
To unlock growth internationally, the business needed its equity story clearly articulated through its public-facing assets. Particularly its scientific credibility and unparalleled proprietary technologies. Shareholders and management recognised that the equity story could not be built only at exit. It had to be embedded early in the hold, shaping every external touchpoint and forming the foundation for long-term valuation.
03. The Delivery & Value
We partnered with shareholders and the USA senior leadership team to build a coherent equity story and communicate it across all public-facing channels. Today, the story presented to the market is unified, world-class and globally relevant across brand, digital and sales.
By aligning public-facing assets to the equity story early in the hold, the business is strengthening its market presence and improving commercial resonance in sophisticated markets.
All identifying details have been fully anonymised to protect the confidentiality of ongoing transaction processes